|
|
|
| Application of CT-guided intracavitary/freehand interstitial brachytherapy in radical radiotherapy for cervical cancer |
| LI Yang, LIU Mengyu, YIN Ping, LI Yue, ZHU Chenjing, LIN Li, ZHANG Siyu, SUN Zhihua, XU Hanzi |
| Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210018 China |
|
|
|
|
Abstract Objective To investigate the clinical application of three-dimensional intracavitary/free-hand interstitial brachytherapy technique in radical radiotherapy for cervical cancer. Methods A retrospective study was conducted on the clinical data of patients with cervical cancer who underwent radical radiotherapy using CT-guided three-dimensional intracavitary/free-hand interstitial brachytherapy technique in The Affiliated Cancer Hospital of Nanjing Medical University from April 2019 to September 2021. The short-term efficacy and adverse reactions were analyzed, and the independent predictors affecting short-term efficacy were evaluated by logistic risk regression model. Results A total of 182 patients were included, and all patients successfully completed the treatment. Clinical efficacy assessment performed 3 months after treatment revealed an overall response rate of 90.65%; the incidence of grade 3 and 4 adverse reactions in the lower gastrointestinal tract was 4.4% during treatment. After reclassifying stage IIIC patients according to the International Federation of Gynecology and Obstetrics (FIGO) 2009 staging system and including factors affecting the stage, it was found that the tumor volume before brachytherapy was the main factor affecting the clinical efficacy of patients at this stage (P = 0.004). Conclusion As a key method in radical radiotherapy for cervical cancer, three-dimensional intracavitary/free-hand interstitial brachytherapy technique is safe and effective and can be quickly popularized in primary hospitals beyond regional cancer centers for cervical cancer brachytherapy.
|
|
Received: 19 March 2024
|
|
|
|
|
|
[1] Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2（1）: 1-9.
[2] 周晖, 刘昀昀, 罗铭, 等. 《2024 NCCN子宫颈癌临床实践指南(第1版)》更新解读[J]. 中国实用妇科与产科杂志, 2023, 39(11): 1119-1121. DOI: 10.19538/j.fk2023110113.
Zhou H, Liu YY, Luo M, et al. Updating and Interpretation of "NCCN guidelines version 1. 2024 cervical cancer"[J]. Chin J Pract Gynecol Obstet, 2023, 39(11): 1119-1121. DOI: 10.19538/j.fk2023110113.
[3] Cibula D, Rosaria Raspollini M, Planchamp F, et al. ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer - update 2023[J]. Radiother Oncol, 2023, 184: 109682.
[4] Onal C, Arslan G, Topkan E, et al. Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses[J]. J Exp Clin Cancer Res, 2009, 28（1）: 95.
[5] Shin KH, Kim TH, Cho JK, et al. CT-guided intracavitary radiotherapy for cervical cancer: comparison of conventional point A plan with clinical target volume-based three-dimensional plan using dose-volume parameters[J]. Int J Radiat Oncol Biol Phys, 2006, 64（1）: 197-204.
[6] Holschneider CH, Petereit DG, Chu C, et al. Brachytherapy: a critical component of primary radiation therapy for cervical cancer: from the society of gynecologic oncology (SGO) and the American brachytherapy society (ABS)[J]. Brachytherapy, 2019, 18（2）: 123-132.
[7] Nomden CN, De Leeuw AAC, Moerland MA, et al. Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 82（4）: 1424-1430.
[8] Dimopoulos JCA, Kirisits C, Petric P, et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: clinical feasibility and preliminary results[J]. Int J Radiat Oncol Biol Phys, 2006, 66（1）: 83-90.
[9] Wang Y, Ye WJ, Du LH, et al. Dose-volume parameters and clinical outcome of CT-guided free-hand high-dose-rate interstitial brachytherapy for cervical cancer[J]. Chin J Cancer, 2012, 31（12）: 598-604.
[10] Cunha JAM, Mellis K, Sethi R, et al. Evaluation of PC-ISO for customized, 3D printed, gynecologic 192Ir HDR brachytherapy applicators[J]. J Applied Clin Med Phys, 2015, 16（1）: 246-253.
[11] 南贤秀, 张洪明, 侯彦杰, 等. 3D打印技术在放疗中的应用与进展[J]. 国际放射医学核医学杂志，2020，44（1）：65-70.
Nan XX, Zhang HM, Hou YJ, et al. Application and progress of 3D printing technology in radiotherapy[J]. Int J Radiat Med Nucl Med, 2020, 44（1）: 65-70.
[12] 张永侠, 袁香坤, 苗珺珺, 等. 3D打印模板应用于局部晚期宫颈癌后装放疗的剂量学研究[J]. 中华放射医学与防护杂志，2020，40（7）：519-523.
Zhang YX, Yuan XK, Miao JJ, et al. Dosimetric analysis of 3D-printed minimally invasive-guided template in the brachytherapy treatment of locally advanced cervical cancer[J]. Chin J Radiol Med Prot, 2020, 40（7）: 519-523.
[13] 王彬冰, 郑光浩, 张翔, 等. 经阴道3D打印个体化模板在宫颈癌后装治疗中的应用价值研究[J]. 中华放射肿瘤学杂志，2020，29（4）：283-288.
Wang BB, Zheng GH, Zhang X, et al. Application value of individualized 3D-printed vaginal template for cervical cancer brachytherapy[J]. Chin J Radiat Oncol, 2020, 29（4）: 283-288.
[14] Yuan XK, Zhang YX, Cui MM, et al. Dosimetry comparison between a 3D printed minimally invasive guidance template and free implantation in the brachytherapy treatment of postoperative recurrent cervical carcinoma[J]. Cancer Manag Res, 2019, 11: 5013-5018.
[15] 赵志鹏, 管薇, 赵红福, 等. 3D打印模板辅助标准化施源器在IIIB期宫颈癌影像引导自适应近距离治疗中的应用[J]. 中华放射肿瘤学杂志，2020，29（8）：661-665.
Zhao ZP, Guan W, Zhao HF, et al. Application of 3D printing technology-assisted standardized applicator in image-guided adaptive brachytherapy of stage Ⅲ B cervical cancer[J]. Chin J Radiat Oncol, 2020, 29（8）: 661-665.
[16] 张菁, 闫庆倩, 杨声. 2020年南京市放射诊疗资源配置现况调查与分析[J]. 中国辐射卫生，2022，31（1）：27-32.
Zhang J, Yan QQ, Yang S. An investigation and analysis of the status of radiological diagnosis and treatment resource allocation in Nanjing, China, 2020[J]. Chin J Radiol Health, 2022, 31（1）: 27-32.
[17] Wu YQ, Zhu BQ, Han JJ, et al. A comparative dosimetric study of cervical cancer patients with para-aortic lymph node metastasis treated with volumetric modulated arc therapy vs. 9-field intensity-modulated radiation therapy[J]. Ann Transl Med, 2019, 7（22）: 675.
[18] HAIE-Meder C, Pötter R, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J]. Radiother Oncol, 2005, 74（3）: 235-245.
[19] Prescribing, recording, and reporting brachytherapy for cancer of the cervix[J]. J ICRU, 2016, 13(1/2): 1-258. DOI: 10.1093/jicru/ndw027.
[20] Schwartz LH, Litière S, De Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee[J]. Eur J Cancer, 2016, 62: 132-137.
[21] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31（5）: 1341-1346.
[22] Tomasevic A, Plesinac Karapandzic V, Stojanovic Rundic S, et al. 3D MRI-based evaluation of the 2D brachytherapy planning in patients with advanced cervical cancer: an analysis of the delivered dose[J]. J BUON, 2020, 25（1）: 108-115.
[23] 谭华艳, 卢敏, 邓烨, 等. 宫颈癌三维后装近距离治疗技术研究进展[J]. 中国辐射卫生，2021，30（3）：371-376.
Tan HY, Lu M, Deng Y, et al. Advances on the technique of three-dimensional intracavitary brachytherapy for cervical cancer[J]. Chin J Radiol Health, 2021, 30（3）: 371-376.
[24] 朱云云, 傅志超, 陈杰, 等. MRI影像与CT影像勾画宫颈癌三维腔内后装放疗靶区体积的比较[J]. 国际放射医学核医学杂志，2020，44（4）：231-235.
Zhu YY, Fu ZC, Chen J, et al. Comparison of the target volumes delineated by MRI and CT images in patients with cervical cancer who received 3D intracavitary brachytherapy[J]. Int J Radiat Med Nucl Med, 2020, 44（4）: 231-235.
[25] Kuipers T, Hoekstra C, Van 'T Riet A, et al. HDR brachytherapy applied to cervical carcinoma with moderate lateral expansion: modified principles of treatment[J]. Radiother Oncol, 2001, 58（1）: 25-30.
[26] Aggarwal L, Mourya A, Choudhary S. Evolution of brachytherapy applicators for the treatment of cervical cancer[J]. J Med Phys, 2021, 46（4）: 231.
[27] 张永侠, 袁香坤, 史福敏, 等. 局部晚期宫颈癌腔内放疗联合组织间插植的剂量学研究[J]. 中华放射医学与防护杂志，2017，37（12）：919-923.
Zhang YX, Yuan XK, Shi FM, et al. A dosimetric analysis of combined intracavitary/interstitial brachytherapy for locally advanced cervical cancer[J]. Chin J Radiol Med Prot, 2017, 37（12）: 919-923.
[28] Wright JD, Matsuo K, Huang YM, et al. Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines[J]. Obstet Gynecol, 2019, 134（1）: 49-57.
[29] 刘萍, 黎志强, 柳攀, 等. FIGO 2018子宫颈癌分期Ⅲ期各亚期设置合理性探讨[J]. 中国实用妇科与产科杂志，2021，37（6）：669-672.
Liu P, Li ZQ, Liu P, et al. Rationality of stage Ⅲ substaging in FIGO 2018 staging of cervical cancer[J]. Chin J Pract Gynecol Obstet, 2021, 37（6）: 669-672.
[30] Pötter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer[J]. Radiother Oncol, 2007, 83（2）: 148-155.
[31] Wang F, Bu LY, Wu Q, et al. Comparison of computed tomography- and magnetic resonance imaging-based target delineation for cervical cancer brachytherapy[J]. J Contemp Brachytherapy, 2020, 12（4）: 367-374.
[32] Hellebust TP. Place of modern imaging in brachytherapy planning[J]. Cancer Radiother, 2018, 22（4）: 326-333.
[33] Wachter-Gerstner N, Wachter S, Reinstadler E, et al. The impact of sectional imaging on dose escalation in endocavitary HDR-brachytherapy of cervical cancer: results of a prospective comparative trial[J]. Radiother Oncol, 2003, 68（1）: 51-59.
|
|
|
|
